Erratum
Year: 2026
Type: erratum
Abstract: In the article “Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis” [Liver Cancer. 2025; https://doi.org/10.1159/000549955] by Chan et al., the copyright license has been changed to a CC-BY 4.0 license. The original online article has been updated to reflect this.
Source: Liver Cancer
DOI: 10.1159/000552217
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,590
OpenAlex ID: W7162517430
Cites:
Cited by:
Related to: